1. Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
   Ruth Plummer et al, 2007, Clinical Cancer Research CrossRef
2. Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Pathway and Its Therapeutic Implications
   Elisabeth G.E. de Vries et al, 2006, Clinical Cancer Research CrossRef
3. Enhancement of Lexatumumab-Induced Apoptosis in Human Solid Cancer Cells by Cisplatin in Caspase-Dependent Manner
   Xiu-Xian Wu et al, 2009, Clinical Cancer Research CrossRef
4. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3′-untranslated region
   Karthikeyan Kandasamy et al, 2008, Molecular Cancer Therapeutics CrossRef
5. Prognostic Value of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer
   Stephan Macher-Goeppinger et al, 2009, Clinical Cancer Research CrossRef
6. Low-Dose 12-O-Tetradecanoylphorbol-13-Acetate Enhances Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis in Prostate Cancer Cells
   Xiaoping Zhang et al, 2007, Clinical Cancer Research CrossRef